Probiotics and prebiotics - renaissance of a therapeutic principle

• Authors: Premysl Fric
• Languages of publication: EN

Abstracts

EN

Probiotics are nonpathogenic microorganisms mostly of human origin which, when administered in adequate amounts, confer a health benefit on the host and enable to prevent or improve some diseases. Probiotics may be a natural temporary constituent of the resident intestinal microflora, but their concentration is not sufficient for therapeutic purposes. The microbiota, the intestinal epithelium, and the mucosal immune system constitute the gastrointestinal ecosystem. All three components are essential for complete functional and developmental maturity of the system. The viability of intestinal microflora (including probiotic strains) requires the availability of nutritional substrates (prebiotics), i.e. various types of fiber and oligosaccharides. Prebiotics are cleaved by microbial enzymes to numerous substances (short-chain fatty acids, aminoacids, polyamines, growth factors, vitamins and antioxidants) indispensable for metabolic and functional activities of the intestinal mucosa. The principal probiotics in use include lactobacilli, bifidobacteria, some nonpathogenic strains of Escherichia coli, and Saccharomyces boulardii. These microbiota display favourable effects which qualify them for therapeutic use. For this purpose, probiotics have to fulfill a series of requirements verifying their efficacy and safety. Experimental and clinical studies examine the prerequisites for the administration of probiotics in digestive diseases, allergic and atopic affections, as well as in some extraintestinal conditions. Future goals of probiotic application include genomic analysis, controlled postnatal colonisation of the digestive tract, the use of probiotics as carriers of peroral vaccines, and recombinant probiotics with in-situ production and targeted application of therapeutic molecules.

Keywords

EN

Gastrointestinal ecosystem; probiotics; prebiotics; synbiotics; microbial interference therapy

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2007
• Volume: 2
• Issue: 3
• Pages: 237-270

Dates

published

1 - 9 - 2007

online

9 - 6 - 2007

Contributors

author

Premysl Fric

• Department of Medicine, First Faculty of Medicine, Charles University and Central Army Hospital, Prague, Czech Republic

References

• [1] R.D. Berg: “The indigenous gastrointestinal microflora”, Trends Microbiol., Vol. 4, (1996), pp. 430–435. [Crossref]
• [2] E.E. Vaughan, F. Schut, H.G. Heilig, E.G. Zoetendal, W.M. de Vosand and A.D. Akkermans: “A molecular view of the intestinal ecosystem”, Cur. Issues Intest. Microbiol., Vol. 1, (2000), pp. 1–12.
• [3] D. Dai and W.A. Walker: “Protective nutrients and bacterial colonisation in the immature human gut”, Adv. Pediatr., Vol. 46, (1999), pp. 353–382.
• [4] K.R. Rozee, D. Cooper, K. Lam and J.W. Costerton: “Microbial flora of the mouse ileum mucosa layer and epithelial surface”, Appl. Environ. Microbiol., Vol. 43, (1982), pp. 1451–1463.
• [5] A. Lee: Neglected niches: “The microbial etiology of the gastrointestinal tract”, In K.C. Marshal (Ed.): Advances in Microbial Ecology, Plenum Press, New York, 1984, pp. 115–162.
• [6] A. Swidsinski, A. Ladhoff, A. Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, J. Weber, U. Hoffmann, S. Schreiber, M. Dietel and H. Lochs: “Mucosal flora in inflammatory bowel disease”, Gastroenterology, Vol.122, (2002), pp. 44–54. [Crossref]
• [7] H. Cheng and C.P. Leblond: “Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine Parts I–V”, Am. J. Anat., Vol. 141 (1974), pp. 461–562.
• [8] P.G. Falk, L.V. Hooper, T. Midtvedt and J.I. Gordon: “Creating and maintaining the gastrointestinal ecosystem: What we know and need to know from gnotobiology”, Microbiol. Mol. Biol. Rev., Vol. 62, (1998), pp. 1157–1170.
• [9] M.F. Kagnoff and L. Eckmann: “Epithelial cells as sensors for microbial infection”, J. Clin. Invest., Vol. 100, (1997), pp. 6–10. [Crossref]
• [10] V.J. Mc Cracken and R.G. Lorenz RG: “The gastrointestinal ecosystem: A precarious alliance among epithelium, immunity and microbiota”, Cellular Microbiology, Vol. 3. (2001), pp. 1–11.
• [11] J.R. Mc Ghee, M.E. Lamm and W. Strober: “Mucosal immune responses: An overview”, In: P.L. Ogra (ed.): Mucosal Immunology, Academic Press, San Diego, 1999, pp. 485–506.
• [12] R.L. Owen: “Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer’s patches - a personal and historical perspective”, Semin. Immunol., Vol. 111, (1999), pp. 157–163.
• [13] M.H. Perdue: “Mucosal immunity and inflammation. III. The mucosal antigen barrier: Cross talk with mucosal cytokines”, Am. J. Physiol., Vol. 277, (1999), pp. G1–G5.
• [14] S.P. James, H. Kiyono: “Gastrointestinal lamina propria T cells”, In P.L. Ogra (Ed.): Mucosal Immunology, Academic Press, San Diego, 1999, pp. 381–396.
• [15] A. Fasano: “Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin”, Ann. N. Y. Acad. Sci., Vol. 915, (2000), pp. 214–222. http://dx.doi.org/10.1111/j.1749-6632.2000.tb05244.x[Crossref]
• [16] W. Wang, S. Uzzau, S.E. Goldblum and A. Fasano: “Human zonulin, a potential modulator of intestinal tight junctions”, J. Cell Sci., Vol. 113, (2000), pp. 4435–4440.
• [17] A. Fasano, A. Not, W. Wang, S. Uzzau, I. Berti, A. Tomassini and S.E. Goldblum: “Zonulin, a newly discovered modulator of intestinal permeability and its expression in coeliac disease”, Lancet, Vol. 355, (2000), pp. 1518–1519. [Crossref]
• [18] M. Di Pierro, R. Lu, S. Uzzau, W. Wang, K. Margaretten, C. Pazzani and F. Maimone: “Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain”, J. Biol. Chem., Vol. 276, (2001), pp. 19160–19165. [Crossref]
• [19] G. Reid, M.E. Sanders, H.R. Gaskins, G.R. Gibson, A. Mercenier, R. Rastall, M. Roberfroid, I. Rowland, C. Cherbut and T.R. Klaenhammer: “New scientific paradigms for probiotics and prebiotics”, J. Clin. Gastroenterol., Vol. 37, (2003), pp. 105–118. [Crossref]
• [20] P. Becquet: “EU assessment of enterococci as feed additives”, Int. J. Food Microbiol., Vol. 88, (2003), pp. 247–254. [Crossref]
• [21] S.L. Gorbach: “Probiotics and gastrointestinal health”, Am. J. Gastroenterol., Vol. 95, (2000), pp. S2–S4.
• [22] D. Rachmilewitz, K. Katakura, F. Karmeli, T. Hayashi, C. Reinus, B. Rudensky, S. Akira, K. Takeda, J. Lee, K. Takabayashi and E. Raz: “Toll-like receptor 9 signalling mediates the antiinflammatory effects of probiotics in murine experimental colitis”, Gastroenterology, Vol. 126, (2004), 520–528. [Crossref]
• [23] R.B. Sartor: Targeting enteric bacteria in treatment of inflammatory bowel diseases: “Why, how and when”, Curr. Opin. Gastroenterol., Vol. 19, (2003), pp. 358–365. [Crossref]
• [24] A. Bolotin, P. Wincker, S. Mauger, O. Jaillon, K. Malarme, J. Weissenbach, S.D. Ehrlich and A. Sorokin: “The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL 1403”, Genome Res., Vol. 11, (2001), pp. 731–753.
• [25] M. Kleerebezem, J. Boekhorst, R. Van Kranenburg, D. Molennar, O.P. Kuipers, R. Leer, R. Tarchini, S.A. Peters, H.M. Sandbrink, M.W. Fiers, W. Stiekema, R.M. Lankhorst, P.A. Bron, S.M. HofferM, M.N. Groot, R. Kerkhoven, M. De Vries, B. Ursing, W.M. De Vos and K.J. Siezen: “Complete genome sequence of Lactobacillus plantarum WCFS1”, Proc. Natl. Acad. Sci. USA, Vol. 100, (2003), pp. 1990–1995.
• [26] M.A. Schell, M. Karmirantzou, B. Snel, D. Vilanova, B. Berger, G. Pessi, M.C. Zwahlen, F. Desiere, P. Bork, M. Delley, E.D. Pridmore and F. Arigoni: “The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract”, Proc. Natl. Acad. Sci. USA, Vol. 99, (2002), pp. 14422–14427. [Crossref]
• [27] L. Grozdanov, C. Raasch, J. Schulze, U. Sonnenborn, G. Gottschalk, J. Hacker and U. Dobrindt: “Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917”, J. Bacteriol., Vol. 186, (2004), pp. 5432–5441. [Crossref]
• [28] J. Sun, F. Gunzer, A.M. Westendorf, J. Buer, M. Scharfe, M. Jarek, F. Gossling, H. Blocker and A.P. Zeng: “Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genomic data”, J. Biotechnol., Vol. 117, (2005), pp. 147–161.
• [29] W.L. Hooper, M.H. Wong, A. Thelin, L. Hansson, P.G. Falk and J.I. Gordon JI: “Molecular analysis of commensal host-microbial relationships in the intestine”, Science, Vol. 291, (2001), pp. 881–884. [Crossref]
• [30] L. Steidler: “Genetically engineered probiotics”, Best Pract. Res. Clin. Gastroenterol., Vol. 17, (2003), pp. 861–876.
• [31] L. Steidler and P. Rottiers: “Therapeutic drug delivery by genetically modified Lactococcus lactis”, Ann. N.Y. Acad. Sci., Vol. 1072, (2006), pp. 176–186.
• [32] P.G. Cano and G. Perdigon: “Probiotics induce resistance to enteropathogens in a re-nourished mouse model”, J. Dairy Res., Vol. 70, (2003), pp. 433–440. [Crossref]
• [33] J. Boudeau, A.L. Glasser, S. Julien, I.F. Colombel and A. Darfeuille-Michaud: “Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn’s disease”, Aliment. Pharmacol. Ther., Vol. 18, (2003), pp. 45–56.
• [34] S. Resta-Lenert and K.E. Barrett: “Live probiotics protect intestinal epithelial cells from the effect of invasion with enteroinvasive Escherichia coli (EIEC)”, Gut, Vol. 52, (2003), pp. 988–997. [Crossref]
• [35] F. Baquero, M.R. Baquero and F. Foreno: Colicins and microcins: “Ecological significance”, In J. Hacker, W. Kruis (eds.): Gut Flora in Symbiosis and Pathogenicity. 3rd Interdisciplinary Symposium A Nissle Gesellschaft, Hagen, 1998, pp. 23–27.
• [36] K.L. Madsen, A. Cornish, P. Soper, C. Mc Kaigney, H. Jijon, C. Yachimec, J. Doyle, L. Jewell and C. De Simone: “Probiotic bacteria enhance murine and human intestinal epithelial barrier function”, Gastroenterology, Vol. 121, (2001), pp. 580–591. [Crossref]
• [37] I. Eizaguirre, N.G. Urkia, I. Ansensio-Abzubillaga, P. Zubillaga, C. Vidales, J.M. Garcia-Arenzana and P. Aldazabal: “Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome”, J. Pediatr. Surg., Vol.37, (2002), pp. 699–702. [Crossref]
• [38] P. Mangell, P. Nejdfors, M. Wang, S. Ahrne, B. Westrom, H. Thorlacius and B. Jeppsson: “Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability”, Dig. Dis. Sci., Vol. 47, (2002), pp. 511–516. [Crossref]
• [39] D.C. Baumgart and A.U. Dignass: “Intestinal barrier function”, Curr. Opin. Clin. Nutr. Metab. Care, Vol. 5, (2002), pp. 685–694. [Crossref]
• [40] H. Ichikawa, T. Kuroiwa, A. Inagaki, R. Shineha, T. Nishihira, S. Satomi and T. Sakata: “Probiotic bacteria stimulate gut epithelial cell proliferation in rat”, Dig. Dis. Sci., Vol. 44, (1999), pp. 2119–2123. [Crossref]
• [41] M. Banasaz, E. Norin, R. Holma, T. Midtvedt: “Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillus rhamnosus GG”, Appl. Environ. Microbiol., Vol. 68, (2002), pp. 3031–3034. [Crossref]
• [42] M. Drakes, T. Blanchard and S. Czinn: “Bacterial probiotic modulation of dendritic cells”, Infect. Immun., Vol. 72, (2004), pp. 3299–3309. [Crossref]
• [43] J.M. Otte and D.K. Podolsky: “Functional modulation of enterocytes by gram-positive and gram-negative microorganisms”, Am. J. Physiol. Gastrointest. Liver Physiol., Vol. 286, (2004), pp. G613–G626. [Crossref]
• [44] B. Cukrowska, R. Lodinova-Zadnikova, C. Enders, U. Sonneborn, J. Schulze and H. Tlaskalova-Hogenova: “Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli Nissle 1917”, Scand. J. Immunol., Vol. 55, (2002), pp. 204–209.
• [45] M. Roller, G. Rechkemmer and B. Watzl: “Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats”, J. Nutr., Vol. 134, (2004), pp. 153–156.
• [46] S. Pathmakanthan, C.K. Li, J. Cowie and C.J. Hawkey: “Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon”, J. Gastroenterol. Hepatol., Vol. 19, (2004), pp. 166–173.
• [47] M.L. Cross: “Immune signalling by orally-delivered probiotic bacteria: Effects on common mucosal immunoresponses and protection at distal mucosal sites”, Int. J. Immunopathol. Pharmacol., Vol. 17, (2004), pp. 127–134.
• [48] A.P. Bai, Q. Ouyang and W. Zhang: “Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells”, World J. Gastroenterol., Vol. 1, (2004), pp. 455–457.
• [49] H. Tlaskalova-Hogenova, R. Stepankova, T. Hudcovic, L. Tuckova, B. Cukrowska, R. Lodinova-Zadnikova, H. Kozakova, P. Rossmann, J. Bartova, D. Sokol, D.P. Funda, D. Borovska, Z. Rehakova, J. Sinkora, J. Hofman, P. Drastich and A. Kokesova: “Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases”, Immunol. Lett., Vol. 93, (2004), pp. 97–108.
• [50] K.M. Chow, Z.C. Liu, S. Prakash and T. Chang: “Free and microencapsulated Lactobacillus and effects of metabolic induction on urea removal”, Artif. Cells Blood Substit. Immobil. Biotechnol., Vol. 31, (2003), pp. 425–434. http://dx.doi.org/10.1081/BIO-120025412[Crossref]
• [51] M. De Roos and M.B. Katan: “Effects of probiotics on diarrhea, lipid metabolism and carcinogenesis: A review of papers published between 1988 and 1998”, Am. J. Clin. Nutr., Vol. 71, (2000), pp. 405–411.
• [52] E.I. Psomas, D.J. Fletouris, E. Litopoulou-Tzanetaki and N. Tzanetaki: “Assimilation of cholesterol by yeast strains isolated from infant feces and Feta cheese”, J. Dairy. Sci., Vol. 86, (2003), pp. 3416–3422. [Crossref]
• [53] S. Nobaek, M.L. Johansson, G. Molin, S. Ahrne and B. Jeppsson: “Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome”, Am. J. Gastroenterol., Vol. 95, (2000), pp. 1231–1238.
• [54] M. Kaliomäki and E. Isolauri: “Pandemic of atopic diseases - a lack of microbial exposure in early infancy?”, Curr. Drug Targets Infect. Disord., Vol. 2, (2002), pp. 193–199. [Crossref]
• [55] W.P. Schmidt: “Model of the epidemic of childhood atopy”, Med. Sci. Monit., Vol. 10, (2004), pp. HY5–9.
• [56] R. Lodinova-Zadnikova and U. Sonnenborn: “Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants”, Biol. Neonate, Vol. 71, (1997), pp. 224–232. http://dx.doi.org/10.1159/000244421[Crossref]
• [57] E. Isolauri, T. Arvola, Y. Sutas, E. Moilanen and S. Salminen: “Probiotics in management of atopic eczema”, Clin. Exp. Allergy, Vol. 30, (2000), pp. 1605–1610. [Crossref]
• [58] M. Kaliomäki and E. Isolauri: “Role of intestinal flora in the development of allergy”, Curr. Opin. Allergy Clin. Immunol., Vol. 3, (2003), pp. 15–20. [Crossref]
• [59] Z. Vancikova, R. Lodinova-Zadnikova, J. Radl and H. Tlaskalova-Hogenova: “The early postnatal development of salivary antibody and immunoglobulin response in children orally colonized with a nonpathogenic, probiotic strain of E. Coli”, Folia Microbiol., Vol. 48, (2003), pp. 281–287. http://dx.doi.org/10.1007/BF02930970[Crossref]
• [60] M. Rinkinen, E. Westermarck, S. Salminen and A.C. Ouwehand: “Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus”, Vet. Microbiol., Vol. 97, (2003), pp. 55–61.
• [61] R.D. Berg: “Bacterial translocation from the gastrointestinal tract”, Adv. Exp. Med. Biol., Vol. 473 (1999), pp. 11–30.
• [62] S.J. Langlands, M.J. Hopkins, N. Coleman and J.H. Cummings: “Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel”, Gut, Vol. 53, (2004), pp. 1610–1616. [Crossref]
• [63] R.A. Rastall: “Bacteria in the gut: Friends and foes and how to alter the balance”, J. Nutr., Vol. 134, (2004), pp. 2022S–2026S.
• [64] K. Whelan, P.A. Judd, V.R. Preedy and M.A. Taylor: Enteral feeding: “The effect on faecal output, the faecal microflora and SCFA concentrations”, Proc. Nutr. Soc., Vol. 63, (2004), pp. 105–113. [Crossref]
• [65] T. Hudcovic, R. Stepankova, J. Cebra and H. Tlaskalova-Hogenova: “The role of microflora in the development of intestinal inflammation: Acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice”, Folia Microbiol., Vol. 46, (2001), pp. 565–572. [Crossref]
• [66] K.L. Madsen, J.S. Doyle, L.D. Jewell, M.M. Tavernini and R.N. Fedorak: “Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice”, Gastroenterology, Vol. 116, (1999), pp. 1107–1114. [Crossref]
• [67] M. Schultz, U.G. Strauch, H.J. Linde, S. Watzl, F. Obermeier, C. Gottl, N. Dunger, N. Grunwald, J. Scholmerich and H.C. Rath: “Preventive effects of E. coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis”, Clin. Diagn. Lab. Immunol., Vol. 11, (2004), pp. 372–378.
• [68] A. Altenhoefer, S. Oswald, U. Sonnenborn, C. Enders, J. Schulze, J. Hacker and T.A. Oelschlaeger: “The probiotic Escherichia coli Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens”, FEMS Immunol. Med. Microbiol., Vol. 40, (2004), pp. 223–229.
• [69] J. Wehkamp, J. Harder, K. Wehkamp, B. Wehkamp-von Meissner, M. Schlee, C. Enders, U. Sonnenborn, S. Nuding, S. Bengmark, K. Fellermann, J.M. Schroder and E.F. Stange: “NF-kappaB and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium”, Infect. Immunol., Vol. 72, (2004), pp. 5750–5758.
• [70] L.A. Dieleman, M.S. Goerres, A. Arends, D. Sprengers, C. Torrice, F. Hoentjen, W.B. Grenther and R.B. Sartor: “Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment”, Gut, Vol. 52, (2003), pp. 370–376. [Crossref]
• [71] R.B. Sartor: “Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics and prebiotics”, Gastroenterology, Vol. 126, (2004), pp. 1620–1633. [Crossref]
• [72] O. Shibolet, F. Karmeli, R. Eliakim, E. Swennen, P. Brigidi, P. Gionchetti, M. Campieri, S. Morgenstern and D. Rachmilewitz: “Variable response to probiotics in two models of experimental colitis in rats”, Inflamm. Bowel Dis., Vol. 8, (2002), pp. 399–406. [Crossref]
• [73] J. Hirano, T. Yoshida, T. Sugiyama N. Koide, T. Mori and T. Yokochi: “The effect of Lactobacillus rhamnosus on enteropathogenic Escherichia coli infection of human intestinal cells in vitro”, Microbiol. Immunol., Vol. 47, (2003), pp. 405–409. [Crossref]
• [74] D.R. Mack, S. Michal, S. Wei, L. Mc Dougall and M.A. Hollingsworth: “Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression”, Am. J. Physiol., Vol. 276, (1999), pp. G941–950.
• [75] C. Pothoulakis, C.P. Kelly, M.A. Joshi, N. Gao, C.J. O’Keane, I. Castagliuolo and J.T. Lamont: “Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum”, Gastroenterology, Vol. 104, (1993), pp. 1108–1115.
• [76] J.P. Buts, N. De Keysser and L. De Raedemaeker: “Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines”, Pediatr. Res., Vol. 36, (1994), pp. 522–527.
• [77] J.I. Alak, B.W. Wolf, E.G. Mdurvwa, G.E. Pimentel-Smith, S. Kolavala, H. Abdelrahman, S. Suppiramaniam: “Supplementation of Lactobacillus reuteri or L. acidophilus reduced intestinal shedding of Cryptosporidium parvum oocysts in immunodeficient C57BL/6 mice”, Cell. Mol. Biol., Vol. 45, (1999), pp. 855–863.
• [78] M. Freitas, E. Tavan, K. Thoreux, C. Cayuela, C. Sapin and G. Trugnan: “Lactobacillus casei DN-114001 and Bacteroides thetaiotaomicron VPI-5482 inhibit rotavirus infection by modulating apical glycosylation pattern of cultured human intestinal HT29-MTX cells”, Gastroenterology, Vol. 124, (2003), pp. A475–476.
• [79] A. Challa, D.R. Rao, C.B. Chawan and L. Shackelford: “Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic abberant crypt foci in rats”, Carcinogenesis, Vol. 18, (1997), pp. 517–521. [Crossref]
• [80] B.S. Reddy: “Possible mechanisms by which pro-and prebiotics influence colon carcinogenesis and tumor growth”, J. Nutr., Vol. 129, (1999), pp. S1478–S1482.
• [81] I. Wollowski, G. Rechkemmer and B.L. Pool-Zobel: “Protective role of probiotics and prebiotics in colon cancer”, Am. J. Clin. Nutr., Vol. 73, (2001), pp. 5451–5455.
• [82] G. Jan, A.S. Belzacq, D. Haouzi, A. Rouault, D. Metivier, G. Kroemer and C. Brenner: “Propionibacteria induce apoptosis of colorectal carcinoma cells via shortchain fatty acids acting on mitochondria”, Cell Death Differ., Vol. 9, (2002), pp. 179–188. [Crossref]
• [83] J. Saikali, C. Picard, M. Freitas and P. Holt: “Fermented milks, probiotic cultures and colon cancer”, Nutr. Cancer, Vol. 49, (2004), pp. 14–24.
• [84] F. Marotta, Y. Naito, E. Minelli, H. Tajiri, J. Borticcelli, C.C. Wu, C.H. Min, P. Hotten and E. Fesce: “Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions”, Hepatogastroenterology, Vol. 50, (2003), pp. 1914–1918.
• [85] C.K. Hsu, J.W. Liao, Y.C. Chung, C.P. Hsieh and Y.C. Chan: “Xylooligosaccharides and fructooligosaccharides affect the intestinal microbiota and precancerous colonic lesion development in rats”, J. Nutr., Vol. 134 (2004), pp. 1523–1528.
• [86] M. Roller, A. Pietro Femia, G. Caderni, G. Rechkemmer and B. Watzl: “Intestinal immunity of rats with colon cancer is modulated by oligofructose enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis”, Br. J. Nutr., Vol. 92, (2004), pp. 931–938. [Crossref]
• [87] J.M. Llovet, R. Bartoli, R. Planas, E. Cabre, M. Jimenez, A. Urban, I. Ojanguren, J. Arnal and M.A. Gassull: “Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis”, Gut, Vol. 35, (1994), pp. 1648–1652. [Crossref]
• [88] J.M. Llovet, R. Bartoli, F. March, R. Planas, B. Vinado, E. Cabre, J. Arnal, P. Coll, V. Ausina and M.A. Gassull: “Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: Molecular epidemic evidence”, J. Hepatol., Vol. 28, (1998), pp. 307–313. [Crossref]
• [89] T.M. Bauer, J. Fernandez, M. Navasa, J. Vila and J. Rodes: “Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis”, J. Hepatol., Vol. 36, (2002), pp. 501–506. [Crossref]
• [90] Z. Li, S. Yang and H. Lin: “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease”, Hepatology, Vol.37, (2003), pp. 343–350. [Crossref]
• [91] G. Mangiante, G. Colucci, P. Canepari, C. Bassi, N. Nicoli, A. Casaril, P. Marinello, C. Signoretto and S. Bengmark: “Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis”, Dig. Surg., Vol. 18, (2001), pp. 47–50.
• [92] S. Akyol, M.R. Mas, B. Comert, U. Ateskan, M. Yasar, H. Aydogan, S. Deveci, C. Akay, H. Mas, N. Yener and I.H. Kocar: “The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis”, Pancreas, Vol. 26, (2003), pp. 363–367. [Crossref]
• [93] K.C. Johnson-Henry, D.J. Mitchell, Y. Avitzur, E. Galindo-Mata, N.L. Jones and P.M. Sherman: “Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice”, Dig. Dis. Sci., Vol. 49, (2004), pp. 1095–1102. [Crossref]
• [94] R. Endersby, J. Walker and H. Jijon: “Probiotic bacteria alternate pro-inflammatory cytokine secretion and maintain colonic permeability in a murine model of sepsis”, Gastroenterology, Vol. 124, (2003), pp. A–477. [Crossref]
• [95] F. Guarner, F. Casellas, N. Borruel, M. Antolin, S. Videla, J. Vilaseca and J.R. Malagelada: “Role of microecology in chronic inflammmatory bowel diseases”, Eur. J. Clin. Nutr., Vol. 56 (Suppl 4), (2002), pp. S34–S38. [Crossref]
• [96] R.N. Fedorak and K. L. Madsen: “Probiotics and the management of inflammatory bowel disease”, Inflamm. Bowel Dis., Vol. 10, (2004), pp. 286–299. [Crossref]
• [97] R.B. Sartor: “Enteric microflora in IBD: Pathogens or commensals?”, Inflamm. Bowel Dis., Vol. 3, (1997), pp. 230–235. [Crossref]
• [98] F. Shanahan: “Probiotics and inflammatory bowel disease: Is there a scientific rationale?”, Inflamm. Bowel Dis., Vol. 6, (2000), pp. 107–115. http://dx.doi.org/10.1002/ibd.3780060208[Crossref]
• [99] P. Fric: “Probiotics in the therapy of idiopathic bowel disease”, Postgrad. Med., Vol. 6, (2004), pp. 123–125.
• [100] R.B. Sartor: “Probiotic therapy of intestinal inflammation and infections”, Curr. Opin. Gastroenterol., Vol. 21, (2005), pp. 44–50.
• [101] E. Schütz: “Behandlung von Darmerkrankungen mit Mutaflor”, Fortschr. Med., Vol. 107, (1989), pp. 599–602.
• [102] K. Plein and J. Hotz: “Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea - a pilot study”, Z. Gastroenterol., Vol. 31, (1993), pp. 129–134.
• [103] M.L. McCann, R.S. Abrams and R.P. Nelson: “Recolonization therapy with nonadhesive Escherichia coli treatment of inflammatory bowel disease”, Ann. N.Y. Acad. Sci., Vol. 730, (1994), pp. 243–245. [Crossref]
• [104] W. Kruis: “Antibiotics and probiotics in inflammatory bowel disease”, Aliment. Pharmacol. Ther., Vol. 20 (Suppl. 4), (2004), pp. 75–78.
• [105] W. Kruis, E. Schutz, P. Fric, B. Fixa, G. Judmaier and M. Stolte: “Double blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis”, Aliment. Pharmacol. Ther., Vol. 11, (1997), pp. 853–858.
• [106] T. Pelech, P. Fric, B. Fixa and O. Komarkova: “Comparison of Mutaflor ® and mesalazine in maintenance therapy of inactive of idiopathic proctocolitis”, Prakt. Lek., Vol. 78, (1998), pp. 556–558.
• [107] B.J. Rembacken, A.M. Snelling, P.M. Hawkey, D.M. Chalmers and A.T. Axon: “Non-pathhogenic Escherichia coli versus mesalalzine for the treatment of ulcerative colitis: a randomised trial”, Lancet, Vol. 354, (1999), pp. 635–639. [Crossref]
• [108] W. Kruis, P. Fric and M. Stolte: “Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nisssle 1917 and standard mesalamine”, Gastroenterology, Vol. 120, (2001), pp. A–127.
• [109] W. Kruis, P. Fric, J. Pokrotnieks, M. Lukas, B. Fixa, M. Kascak, M. A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, C. Wolff and J. Schulze: “Maintaining remission of ulcerative colitis with the probiotic Eschericia coli Nissle 1917 is as effective as with standard mesalazine”, Gut, Vol. 53, (2004), pp. 1617–1623.
• [110] A. Venturi, P. Gionchetti, F. Rizzello, R. Johansson, E. Zucconi, P. Brigidi, D. Matteuzzi and M. Campieri: “Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis”, Aliment. Pharmacol. Ther., Vol. 13, (1999), pp. 1103–1108.
• [111] H. Ishikawa, I. Akedo, Y. Umesaki, R. Tanaka, A. Imaoka and T. Otani: “Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis”, J. Am. Coll. Nutr., Vol. 22, (2003), pp. 56–63. [Crossref]
• [112] M. Guslandi, P. Giollo and P.A. Testoni: “A pilot trial of Saccharomyces boulardii in ulcerative colitis”, Eur. J. Gastroenterol. Hepatol., Vol. 15, (2003), pp. 697–698. [Crossref]
• [113] A. Tursi, G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo and A. Gigliobianco: “Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-tomoderate ulcerative colitis”, Med. Sci. Monit., Vol. 10, (2004), pp. 126–131.
• [114] E. Furrie, S. Macfarlane, A. Kennedy, J.H. Cummings, S.V. Walsh, D.A. O’Neil and G.T. Macfarlane: “Synbiotic therapy (Bifidobacterium longum/Synergy) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial”, Gut, Vol. 54, (2005), pp. 242–249. [Crossref]
• [115] H.R. Malchow: “Crohn’s disease and Escherichia coli. A novel approach in therapy to maintain remission of colonic Crohn’s disease?”, J. Clin. Gastroenterol., Vol. 25, (1997), pp. 653–658. [Crossref]
• [116] M. Guslandi, G. Mezzi, M. Sorghi and P.A. Testoni: “Saccharomyces boulardii in maintenance treatment of Crohn’s disease”, Dig. Dis. Sci., Vol. 45, (2000), pp. 1462–1464. [Crossref]
• [117] M. Campieri, F. Rizzello and A. Venturi: “Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease”, Gastroenterology, Vol. 118, (2000), pp. A–781. [Crossref]
• [118] P. Gionchetti, F. Rizzello, U. Helwig, A. Venturi, K.M. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli and M. Campieri: “Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial”, Gastroenterology, Vol. 124, (2003), pp. 1202–1209. [Crossref]
• [119] P. Gionchetti, C. Morselli, F. Rizzello, R. Romagnoli, M. Campieri, G. Poggioli, S. Laureti, F. Ugolini and F. Pierangeli: “Management of pouch dysfunction or pouchitis with an ileoanal pouch”, Best. Pract. Res. Clin. Gastroenterol., Vol. 18, (2004), pp. 993–1006. [Crossref]
• [120] P. Gionchetti, F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli and M. Campieri: “Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial”, Gastroenterology, Vol. 119, (2000), pp. 305–309. [Crossref]
• [121] K.O. Laake, P.D. Line, L. Aabakken, T. Lotveit, A. Bakka, J. Eide, A. Roseth, K. Grzyb, A. Bjorneklett and M. H. Vatn: “Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis”, Scand. J. Gastroenterol., Vol. 38, (2003), pp. 409–414.
• [122] J. Kuisma, S. Mentula, H. Jarvinen, A. Kahri, M. Saxelin and M. Farkkila: “Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora”, Aliment. Pharmacol. Ther., Vol. 17, (2003), pp. 509–515.
• [123] J.M. Saavedra, N.A. Bauman, I. Oung, J.A. Perman and R.H. Yolken: “Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus”, Lancet, Vol. 344, (1994), pp. 1046–1049. [Crossref]
• [124] S. Guandalini, L. Pensabene and M.A. Zikri: “Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: A multicenter European trial”, J. Pediatr. Gastroenterol. Nutr., Vol. 30, (2000), pp. 54–60. [Crossref]
• [125] H. Costa-Ribeiro, T.C. Ribeiro, A.P. Mattos, S.S. Valois, D.A. Neri, P. Almeida, C.M. Cerqueira, E. Ramos, R.J. Young and J.A. Vanderhoof: “Limitations of probiotic therapy in acute, severe dehydrating diarrhea”, J. Pediatr. Gastroenterol. Nutr., Vol. 36, (2003), pp. 112–115. [Crossref]
• [126] H. RibeiroJr: “Diarrheal disease in a developing nation”, Am. J. Gastroenterol., Vol. 95 (Suppl. 1), (2000), pp. S14–S15.
• [127] M. Kaila, E. Isolauri E. Soppi, E. Virtanen, S. Laine and H. Arvilommi: “Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain”, Pediatr. Res., Vol. 32, (1992), pp. 141–144.
• [128] R. Lodinova-Zadnikova, H. Tlaskalova-Hogenova and U. Sonnenborn: “Local and serum antibody response in full-term and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor ®)”, Pediatr. Allergy Immunol., Vol. 3, (1992), pp. 43–48.
• [129] L.V. McFarland, C.M. Surawicz, R.N. Greenberg, R. Fekety, G.W. Elmer, K.A. Moyer, S.A. Melcher, K. E. Bowen, J.L. Cox and Z. Noorani: “A randomized placebocontrolled trial of Saccharomyces boulardii in combination wit standard antibiotics for Clostridium difficile disease”, JAMA, Vol. 271, (1994), pp. 1913–1918. [Crossref]
• [130] C.M. Surawicz, L.V. McFarland, G.W. Elmer and J. Chinn: “Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii”, Am. J. Gastroenterol., Vol. 84, (1989), pp. 1285–1287.
• [131] S.L. Gorbach, T.W. Chang and G. Goldin: “Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG”, Lancet, Vol. 2, (1987), p. 1519. [Crossref]
• [132] M. Pochapin: “The effect of probiotics on Clostridium difficile diarrhea”, Am. J. Gastroenterol., Vol. 95, (2000), pp. S11–S13.
• [133] S. Plummer, M.A. Weawer, J.C. Harris, P. Dee and J. Hunter: “Clostridium difficile pilot study: Effects of probiotic supplementation on the incidence of C. difficile diarrhoea”, Int. Microbiol., Vol. 7, (2004), pp. 59–62.
• [134] A.L. D’souza, C. Rajkumar, J. Cooke and C.J. Bulpitt: “Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis”, Brit. Med. J., Vol. 324, (2002), p. 1361. [Crossref]
• [135] J.A. Vanderhoof, D.B. Whitney, D.L. Antonson, T.L. Hanner, J.V. Lupo and R.J. Young: “Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children”, J. Pediatr., Vol. 135, (1999), pp. 564–568. [Crossref]
• [136] T. Arvola, K. Laiho, S. Torkkeli, H. Mykkanen, S. Salminen, L. Maunula and E. Isolauri: “Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections”, Pediatrics, Vol. 104, (1999), p. e64. [Crossref]
• [137] H. Kollaritsch, H. Holst, P. Grobara and G. Wiedermann: “Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study”, Fortschr. Med., Vol. 111, (1993), pp. 152–156.
• [138] E. Hilton, P. Kolakowski, C. Singer and M. Smith: “Efficacy of Lactobacillus GG as a diarrheal preventive in travelers”, J. Travel. Med., Vol. 4, (1997), pp. 41–43. [Crossref]
• [139] A. Tromm, U. Niewerth, M. Khoury, E. Baestline, G. Wilhelms, J. Schulze and M. Stolte: “The probiotic E. coli Nissle 1917 for the treatment of collagenous colitis: First results of an open-label trial”, Z. Gastroenterol., Vol. 42, (2004), pp. 365–369.
• [140] A. Balsari, A. Ceccarelli and F. Dubini: “The faecal bacterial population in the irritable bowel syndrome”, Microbiologica, Vol. 5, (1982), pp. 185–194.
• [141] A. Swidsinski, M. Khilkin and M. Ortner: “Alteration of bacterial concentration in colonic biopsies from patients with irritable bowel syndrome (IBS)”, Gastroenterology, Vol. 115, (1999), pp. A–1.
• [142] T.S. King, M. Elia and J.O. Hunter: “Abnormal colonic fermentation in irritable bowel syndrome”, Lancet, Vol. 352, (1998), pp. 1187–1189. [Crossref]
• [143] G.M. Halpern, T. Prindville, M. Blankenburg, T. Hsia and M.E. Gershwin: “Treatment of irritable bowel syndrome with Lacteol forte: A randomized, double-blind, cross-over trial”, Am. J. Gastroenterol., Vol. 91, (1996), pp. 1579–1585.
• [144] M.A. O’sullivan and C.A. O’Morain CA: “Bacterial supplementation in the irritable bowel syndrome: A randomized, double-blind, placebo-controlled crossover study”, Digest. Liver. Dis., Vol. 32, (2000), pp. 294–301. [Crossref]
• [145] H.J. Kim, M. Camilleri, S. Mc Kinzie, M.B. Lempke, D.D. Burton, G.M. Thomforde and A.R. Zinsmeister: “A randomized controlled trial of a probiotic, VSL 3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome”, Aliment. Pharmacol. Ther., Vol. 17, (2003), pp. 895–904.
• [146] A. Saggioro: “Probiotics in the treatment of irritable bowel syndrome”, J. Clin. Gastroenterol., Vol. 38, (2004), pp. S104–106. [Crossref]
• [147] M. Möllenbrink and E. Bruckschen: “Treatment of chronic constipation with physiological E. coli bacteria. Results of a clinical trial on the efficacy and compatibility of microbiological therapy with the E. coli strain Nissle 1917 (Mutaflor ®)”, Med. Klin., Vol. 89, (1994), pp. 587–593.
• [148] E. Bruckschen and H. Horosiewicz: “Chronische Obstipation. Vergleich von mikrobiologischer Therapie und Laktulose”, Münch. Med. Wschr., Vol. 16, (1994), pp. 241–245.
• [149] C. Koebnick, I. Wagner, P. Leitzmann, U. Stern and H.J. Zunft: “Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation”, Canad. J. Gastroenterol., Vol. 17 (2003), pp. 655–659.
• [150] S.M. Faber: “Comparison of probiotics and antibiotics to probiotics alone in treatment of diarrhea predominant IBS (D-IBS), alternating (A-IBS) and constipation (C-IBS) patients”, Gastroenterology, Vol. 118, (2000), pp. A687–688. http://dx.doi.org/10.1016/S0016-5085(00)80504-1[Crossref]
• [151] P. Fric and M. Zavoral: “The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon”, Eur. J. Gastroenterol. Hepatol., Vol. 15, (2003), pp. 313–315. [Crossref]
• [152] T.M. Bauer, B. Steinbruckner, F.E. Brinkman, A.K. Ditzen, H. Schwacha, J.J. Aponte, K. Pelz, M. Kist and H.E. Blum: “Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis”, Am. J. Gastroenterol., Vol. 96, (2001), pp. 2962–2967.
• [153] T.M. Bauer, H. Schwacha, B. Steinbruckner, F.E. Brinkmann, A.K. Ditzen, J.J. Aponte, K. Pelz, D. Berger, M. Kist and H.E. Blum: “Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia”, Am. J. Gastroenterol., Vol. 97, (2002), pp. 2364–2370.
• [154] I. Cirera, T.M. Bauer, M. Navasa, J. Vila, L. Grande, P. Taura, J.J. Fuster, J.C. Garcia-Valdecasas, A. Lacy, M.J. Suarez, A. Rimola and J. Rodes: “Bacterial translocation of enteric organisms in patients with cirrhosis”, J. Hepatol., Vol.34, (2001), pp. 32–37. [Crossref]
• [155] S. Pascual, J. Such, A. Esteban, P. Zapater, J.A. Casellas, J.R. Aparicio, E. Girona, A. Gutierrez, F. Carnices, J.M. Palazon, J. Sola-Vera and M. Perez-Mateo: “Intestinal permeability is increased in patients with advanced cirrhosis”, Hepatogastroenterology, Vol. 50, (2003), pp. 1482–1486.
• [156] Di Leo, C. Venturi, A. Baragiotta, D. Martines and A. Floreani: “Gastroduodenal and intestinal permeability in primary biliary cirrhosis”, Eur. J. Gastroenterol. Hepatol., Vol. 15, (2003), pp. 967–973.
• [157] B. Campillo, P. Pernet, P.N. Bories, J.P. Richardet, M. Devanlay and C. Aussel: “Intestinal permeability in liver cirrhosis: Relationship with severe septic complications”, Eur. J. Gastroenterol. Hepatol., Vol. 11, (1999), pp. 755–759. [Crossref]
• [158] S.F. Solga: “Probiotics can treat hepatic encephalopathy”, Med. Hypotheses, Vol. 61, (2003), pp. 307–313. [Crossref]
• [159] G. Bongaerts, R. Severijnen and H. Timmerman: “Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy”, Med. Hypotheses, Vol. 64, (2005), pp. 64–68. [Crossref]
• [160] M. Boca, M. Vyskocil, M. Mikulecky, L. Ebringer, E. Kolibas, H. Kratochvilova and D. Buzgova: “Complex therapy of chronic hepatic encephalopathy supplemented with a probiotic: comparison of two studies”, Cas. Lek. Cesk., Vol. 143, (2004), pp. 324–328.
• [161] Q. Liu, Z.P. Duan, D.K. Ha, S. Bengmark, J. Kurtovic and S.M. Riordan: “Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis”, Hepatology, Vol. 39, (2004), pp. 1441–1449. [Crossref]
• [162] J. Medina, L.I. Fernandez-Salazar, L. Garcia-Buey and R. Moreno-Otero: “Approach to the pathogenesis and treatment of nonalcoholic steatohepatosis”, Diabetes Care, Vol. 27, (2004), pp. 2057–2066.
• [163] C.S. Chang, S.S. Yang, C.H. Kao, H.Z. Yeh and G.H. Chen: “Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis”, Scand. J. Gastroenterol., Vol. 36, (2001), pp. 92–96. http://dx.doi.org/10.1080/00365520150218110[Crossref]
• [164] L. Ruiz-del-Arbol, J. Urman, J. Fernandez, M. Gonzales, M. Navasa, A. Monescillo, A. Albillos, W. Jimenez and W. Arroyo: “Systemic, renal and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis”, Hepatology, Vol. 38, (2003), pp. 1210–1218. [Crossref]
• [165] A. Olah, T. Belagyi, A. Issekurz, M.E. Gamal and S. Bengmark: “Randomized clinical trial of specific Lactobacillus and fibre supplement to early nutrition in patients with acute pancreatitis”, Brit. J. Surg., Vol. 89, (2002), pp. 1103–1007.
• [166] K.Y. Wang, S.N. Li, C.S. Liu, D.S. Perng, Y.C. Su, D.C. Wu, C.M. Jan, C.H. Lai, T.N. Wang and W.M Wang: “Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori”, Am. J. Clin. Nutr., Vol. 80, (2004), pp. 737–741.
• [167] M. Linsalata, F. Russo, P. Berloco, M.L. Caruso, G.D. Matteo, M.G. Cifone, C.D. Simone, E. Ierardi and A. Di Leo: “The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa”, Helicobacter, Vol. 9, (2004), pp. 165–172. [Crossref]
• [168] F. Cremonini, S. Di Caro, M. Covino, A. Armuzzi, M. Gabrielli, L. Santarelli, E.C. Nista, G. Cammarota, G. Gasbarrini and A. Gasbarrini: “Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel-group, triple-blind, placebo-controlled study”, Am. J. Gastroenterol., Vol. 97, (2002), pp. 2744–2749.
• [169] J.M. Hamilton-Miller: “The role of probiotics in the treatment and prevention of Helicobacter pylori infection”, Int. J. Antimicrob. Agents, Vol. 22, (2003), pp. 360–366.
• [170] R. Lodinova-Zadnikova, H. Tlaskalova and Z. Bartakova: “The antibody response in infants after colonization of the intestine with E. coli O83. Artificial colonization used as prevention against nosocomial infections”, Adv. Exp. Biol. Med., Vol. 310, (1991), pp. 329–333.
• [171] R. Lodinova-Zadnikova, M. Slavikova, H. Tlaskalova-Hogenova, I. Adlerberth, L.A. Hanson, A. Wold, B. Carlsson, C. Svanborg and L. Mellander: “The antibody response in breast-fed and non-breast-fed infants after artificial colonization of the intestine with Escherichia coli O83”, Pediatr. Res., Vol. 29, (1991), pp. 396–399.
• [172] R. Lodinova-Zadnikova, B. Cukrowska and H. Tlaskalova-Hogenova: “Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years)”, Int. Arch. Allergy Immunol., Vol. 131, (2003), pp. 209–211.
• [173] M. Kaliomäki, S. Salminen, H. Arvilommi, P. Kero, P. Koskinen and E. Isolauri: “Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial”, Lancet, Vol. 357, (2001), pp. 1076–1079. [Crossref]
• [174] M. Kaliomäki, S. Salminen, T. Poussa, H. Arvilommi and E. Isolauri: “Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial”, Lancet, Vol. 361, (2003), pp. 1869–1871. [Crossref]
• [175] V. Rosenfeldt, E. Benfeldt, S.D. Nielsen, K.F. Michaelsen, D.L. Jeppesen, N.H. Valerius and A. Paerregaard: “Effect of probiotic Lactobacillus strains in children with atopic dermatitis”, J. Allergy Clin. Immunol., Vol. 111, (2003), pp. 389–395. [Crossref]
• [176] M. Viljanen, E. Savilahti, T. Haahtela, K. Juntunen-Backman, R. Korpela, T. Poussa, T. Tuure and M. Kuitunen: “Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: A double-blind placebo-controlled trial”, Allergy, Vol. 60, (2005), pp. 494–500. [Crossref]
• [177] S. Bengmark: “Use of some pre-, pro-and synbiotics in critically ill patients”, Best. Pract. Res. Clin. Gastroenterol., Vol. 17, (2003), pp. 833–848. [Crossref]
• [178] P.K. Jain, C.E. McNaught, A.D. Anderson, J. MacFie and C.J. Mitchell: “Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: A randomised controlled trial”, Clin. Nutr., Vol. 23, (2004), pp. 467–475.
• [179] A.D. Anderson, C.E. McNaught, P.K. Jain and J. MacFie: “Randomised clinical trial of synbiotic therapy in elective surgical patients”, Gut, Vol. 53, (2004), pp. 241–245. [Crossref]
• [180] N. Rayes, D. Seehofer, T. Theruvath, R.A. Schiller, J.M. Langrehr, S. Jonas, S. Bengmark and P. Neuhaus: “Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial”, Am. J. Transplant., Vol. 5, (2005), pp. 125–130. [Crossref]
• [181] H. Fang, T. Elina, A. Heikki and S. Seppo: “Modulation of humoral immune response through probiotic intake”, FEMS Immunol. Med. Microbiol., Vol. 29, (2000), pp. 47–52. [Crossref]
• [182] C. Grangette, H. Müller-Alouf, D. Goudercourt, M.C. Geoffroy, M. Turneer and A Mercenier: “Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum”, Infect. Immun., Vol. 69, (2001), pp. 1547–1553. [Crossref]
• [183] H. Duc le and S.M. Cutting: “Bacterial spores as heat stable vaccine vehicles”, Expert Opin. Biol. Ther., Vol. 3, (2003), pp. 1263–1270.
• [184] S. Rao, S. Hu, L. McHugh, K. Lueders, K. Henry, Q. Zhao, R.A. Fekete, S. Kar, S. Adhya and D.H. Hamer: “Toward a live microbial microbicide for HIV: Commensal bacteria secreting an HIV fusion inhibitor peptide”, Proc. Natl. Acad. Sci., Vol. 102, (2005), pp. 11993–11998. [Crossref]
• [185] A.M. Westendorf, F. Gunzer, S. Deppenmeier, D. Tapadar, J.K. Hunger, M.A. Schmidt, J. Buer and D. Bruder: “Intestinal immunity of Escherichia coli Nissle 1917: A safe carrier for therapeutic molecules”, FEMS Immunol. Med. Microbiol., Vol. 43, (2005), 373–384.
• [186] M.K. Salminen, S. Tynkkynen, H. Rautelin, M. Saxelin, M. Vaara, P. Ruutu, S. Sarna, V. Valtonen and A. Jarvinen: “Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland”, Clin. Infect. Dis., Vol. 35, (2002), 1155–1160. [Crossref]
• [187] Z. Lherm, C. Monet, B. Nougiere, B. Soulier, D. Larbi, C. De Gall, D. Caen and C. Malbrunot: “Seven cases of fungemia with Saccharomyces boulardii in critically ill patients”, Intensive Care Med., Vol. 28, (2002), pp.797–801.
• [188] A.J. Riquelme, M.A. Calvo, A.M. Guzman, M.S. Depix, P. Garcia, C. Perez, M. Arrese and J.A. Labarca: “Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients”, J. Clin. Gastroenterol., Vol. 36, (2003), pp. 41–43. [Crossref]
• [189] F. Lestin, A. Pertschy and D. Rimek: “Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple co-morbidities”, Dtsch. Med. Wschr., Vol. 128, (2003), pp. 2531–2533.

Identifiers

DOI

10.2478/s11536-007-0031-5